20 "Past Their Prime" Stocks to Dump From Your Portfolio in 2018

Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2017. Even just 15 years ago, companies like Radio Shack, AOL, Yahoo and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.

As the years go by, some companies lose their luster and others rise to the top of the markets. We've already seen this in the last few decades with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega trend will be that will knock Apple, Google and Amazon off the top rankings of the S&P 500, but we do know that companies won't stay on the S&P 500 forever.

We've identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they are showing negative earnings growth for the next several years. If you own any of these stocks, consider selling them now before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.

#1 - Sprint (NYSE:S)

Trailing Twelve Months EPS: ($0.28)
2018 EPS Estimate: ($0.01)
2019 EPS Estimate: ($0.07)

Current Price: $5.88
P/E Ratio: -21.0
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 11 Hold Ratings, 6 Sell Ratings.
Consensus Price Target: $5.5714 (-5.2% Upside)

Sprint Corporation, through its subsidiaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the U.S. Virgin Islands. The company operates in two segments, Wireless and Wireline. The Wireless segment offers wireless data communication services, including mobile productivity applications, such as Internet access, messaging, and email services; wireless photo and video offerings; location-based capabilities comprising asset and fleet management, dispatch services, and navigation tools; and mobile entertainment applications. It also provides wireless voice communications services that include local and long-distance wireless voice services, as well as voicemail, call waiting, three-way calling, caller identification, directory assistance, and call forwarding services. In addition, this segment offers voice and data services internationally through roaming arrangements; and customized wireless services to large companies and government agencies, as well as sells wireless devices, broadband devices, connected devices, and accessories to agents and other third-party distributors. The Wireline segment provides wireline voice and data communications, including domestic and international data communications using various protocols, such as multiprotocol label switching technologies, Internet protocol (IP), managed network services, Voice over IP, session initiated protocol, and traditional voice services to other communications companies, and targeted business subscribers. Sprint Corporation offers its services under the Sprint, Boost Mobile, Virgin Mobile, and Assurance Wireless brands. It offers products through its 300 branded retail locations in the Southern California region. The company was founded in 1899 and is headquartered in Overland Park, Kansas. Sprint Corporation is a subsidiary of SoftBank Group Corp.

#2 - AU Optronics (NYSE:AUO)

Trailing Twelve Months EPS: $1.13
2018 EPS Estimate: $0.09
2019 EPS Estimate: ($0.83)

Current Price: $4.10
P/E Ratio: 3.6
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 2 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: N/A

AU Optronics Corp. researches, develops, produces, and sells thin film transistor liquid crystal displays and other flat panel displays. The company operates through two segments, Display and Solar. The Display segment designs, develops, manufactures, assembles, and markets flat panel displays for use in televisions, TV sets, and other related products; desktop monitors; mobile PCs, such as notebooks and tablets; mobile phones; and commercial and other applications, including displays for automobiles, industrial PCs, automated teller machines, point of sale terminals, pachinko machines, and others. It sells its panels to original equipment manufacturing service providers; and brand companies. The Solar segment manufactures and sells solar materials, including ingots, solar wafers, and solar modules, as well as provides technical engineering and maintenance services for solar system projects. This segment sells its ingot and solar wafer products primarily to solar cell manufacturers; and solar modules to installers, solar system integrators, property developers, and other value-added resellers. The company also engages in the renewable energy power generation; repairing of TFT-LCD modules; injecting and stamping parts; manufacture and sale of molds, light guide plates, backlight modules, and related parts, as well as precision plastic and metal parts; and IP related business. It operates in the People's Republic of China, Taiwan, Japan, Singapore, Malaysia, and internationally. AU Optronics Corp. was founded in 1996 and is headquartered in Hsinchu, Taiwan.

#3 - Sangamo Therapeutics (NASDAQ:SGMO)

Trailing Twelve Months EPS: ($0.70)
2018 EPS Estimate: ($0.15)
2019 EPS Estimate: ($0.62)

Current Price: $18.15
P/E Ratio: -25.9
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $22.20 (22.3% Upside)

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

#4 - Loxo Oncology (NASDAQ:LOXO)

Trailing Twelve Months EPS: ($5.31)
2018 EPS Estimate: $0.30
2019 EPS Estimate: ($1.81)

Current Price: $133.06
P/E Ratio: -25.1
Consensus Rating: Buy
Ratings Breakdown: 11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $129.8750 (-2.4% Upside)

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

#5 - Tellurian (NASDAQ:TELL)

Trailing Twelve Months EPS: ($0.82)
2018 EPS Estimate: ($0.31)
2019 EPS Estimate: ($0.69)

Current Price: $10.35
P/E Ratio: -12.6
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.50 (20.8% Upside)

Tellurian Inc. plans to develop, own, and operate a natural gas business and to deliver natural gas to customers worldwide. The company is developing a portfolio of natural gas production, liquefied natural gas (LNG) trading, and infrastructure that includes an approximately 27.6 million tons per annum LNG export facility and an associated pipeline. As of December 31, 2017, it owned interests in approximately 11,844 net developed and undeveloped acres of natural gas properties in northern Louisiana. The company was founded in 2015 and is headquartered in Houston, Texas.

#6 - Denali Therapeutics (NASDAQ:DNLI)

Trailing Twelve Months EPS: ($5.89)
2018 EPS Estimate: ($0.56)
2019 EPS Estimate: ($1.46)

Current Price: $19.45
P/E Ratio: -3.3
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $24.00 (23.4% Upside)

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

#7 - Acorda Therapeutics (NASDAQ:ACOR)

Trailing Twelve Months EPS: $1.04
2018 EPS Estimate: ($0.94)
2019 EPS Estimate: ($3.93)

Current Price: $23.35
P/E Ratio: 22.5
Consensus Rating: Hold
Ratings Breakdown: 3 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $21.8333 (-6.5% Upside)

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

#8 - Hutchison China MediTech (NASDAQ:HCM)

Trailing Twelve Months EPS: ($0.22)
2018 EPS Estimate: ($0.45)
2019 EPS Estimate: ($0.62)

Current Price: $32.96
P/E Ratio: -149.8
Consensus Rating: Buy
Ratings Breakdown: 1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $38.00 (15.3% Upside)

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical drug candidates include Savolitinib, an inhibitor for treating non-small cell lung, colorectal, and gastric cancer, as well as papillary renal cell carcinoma; Fruquintinib, an oral inhibitor for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib for treating neuroendocrine tumors, and thyroid and biliary tract cancer; and Epitinib for the treatment of non-small cell lung cancer, as well as for patients with glioblastoma. The company also develops Theliatinib epidermal growth factor receptor inhibitor for treating solid tumors, as well as for patients with esophageal cancer; HMPL-523, an oral inhibitor for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a small molecule inhibitor for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453, a small molecule inhibitor for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

#9 - Alkermes (NASDAQ:ALKS)

Trailing Twelve Months EPS: ($0.37)
2018 EPS Estimate: ($0.57)
2019 EPS Estimate: ($0.70)

Current Price: $45.18
P/E Ratio: -122.1
Consensus Rating: Hold
Ratings Breakdown: 4 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $60.6364 (34.2% Upside)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

#10 - Pacira Pharmaceuticals (NASDAQ:PCRX)

Trailing Twelve Months EPS: ($0.58)
2018 EPS Estimate: ($0.51)
2019 EPS Estimate: ($0.54)

Current Price: $35.40
P/E Ratio: -61.0
Consensus Rating: Hold
Ratings Breakdown: 8 Buy Ratings, 11 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $44.50 (25.7% Upside)

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

#11 - MuleSoft (NYSE:MULE)

Trailing Twelve Months EPS: ($0.67)
2018 EPS Estimate: ($0.63)
2019 EPS Estimate: ($0.73)

Current Price: $44.52
P/E Ratio: -66.4
Consensus Rating: Hold
Ratings Breakdown: 3 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $33.3333 (-25.1% Upside)

MuleSoft, Inc. provides Anypoint Platform that allows customers to connect their applications, data, and devices in the United States, the United Kingdom, and internationally. Its platform also enables a self-serve infrastructure through discoverable building blocks or nodes that can be used and reused to compose applications. Its customers use these building blocks to connect their SaaS applications, on-premises applications, cloud deployments, mobile devices, and data into an application network. MuleSoft, Inc. has a strategic alliance with IQVIA. The company was formerly known as MuleSource, Inc. and changed its name to MuleSoft, Inc. in August 2009. MuleSoft, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

#12 - Adaptimmune Therapeutics (NASDAQ:ADAP)

Trailing Twelve Months EPS: ($0.80)
2018 EPS Estimate: ($0.82)
2019 EPS Estimate: ($1.20)

Current Price: $12.29
P/E Ratio: -15.4
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $15.00 (22.1% Upside)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma. It is also developing MAGE A-10 peptide that is in Phase I/II clinical trials to treat urothelial (bladder), melanoma, and head and neck cancers, as well as NSCLC; AFP SPEAR T-cell therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma; and MAGE-A4 to treat urothelial (bladder), melanoma, head and neck, esophageal and gastric, and ovarian cancer, as well as NSCLC. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a collaboration agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.

#13 - Liberty Media (NASDAQ:FWONK)

Trailing Twelve Months EPS: $1.21
2018 EPS Estimate: ($0.66)
2019 EPS Estimate: ($0.70)

Current Price: $30.70
P/E Ratio: 32.5
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $41.40 (34.9% Upside)

Formula One Group, through its subsidiaries, engages in the media and entertainment businesses in North America. Formula One Group was formerly known as The Liberty Media Group. The company is based in Englewood, Colorado. Formula One Group is a former subsidiary of Liberty Media Corporation.

#14 - arGEN-X BV (NASDAQ:ARGX)

2018 EPS Estimate: ($1.28)
2019 EPS Estimate: ($2.53)

Current Price: $87.74
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $88.25 (0.6% Upside)

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

#15 - Yext (NYSE:YEXT)

Trailing Twelve Months EPS: ($0.85)
2018 EPS Estimate: ($0.70)
2019 EPS Estimate: ($0.73)

Current Price: $13.51
P/E Ratio: -15.9
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $16.00 (18.4% Upside)

Yext, Inc. provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud in North America and Europe. The company offers Yext Knowledge Engine, a cloud-based global platform that enables businesses to control and manage their digital knowledge and make it available through its PowerListings Network of approximately 150 third-party maps, apps, search engines, intelligent GPS systems, digital assistants, vertical directories, and social networks. Yext, Inc. serves healthcare, retail, and financial services industries. The company was founded in 2006 and is based in New York, New York.

#16 - MyoKardia (NASDAQ:MYOK)

Trailing Twelve Months EPS: ($1.40)
2018 EPS Estimate: ($1.35)
2019 EPS Estimate: ($2.37)

Current Price: $50.05
P/E Ratio: -35.8
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $66.6667 (33.2% Upside)

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

#17 - Apellis Pharmaceuticals (NASDAQ:APLS)

Trailing Twelve Months EPS: ($3.67)
2018 EPS Estimate: ($1.16)
2019 EPS Estimate: ($1.45)

Current Price: $23.42
P/E Ratio: -6.7
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $28.3333 (21.0% Upside)

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.

#18 - CytomX Therapeutics (NASDAQ:CTMX)

Trailing Twelve Months EPS: ($1.16)
2018 EPS Estimate: ($1.44)
2019 EPS Estimate: ($2.07)

Current Price: $26.57
P/E Ratio: -22.9
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $40.1667 (51.2% Upside)

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

#19 - Coupa (NASDAQ:COUP)

Trailing Twelve Months EPS: ($0.76)
2018 EPS Estimate: ($1.16)
2019 EPS Estimate: ($1.20)

Current Price: $49.70
P/E Ratio: -65.4
Consensus Rating: Buy
Ratings Breakdown: 12 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $46.4375 (-6.6% Upside)

Coupa Software Incorporated provides cloud-based spend management platform. The company's platform connects organization with suppliers globally; and provides visibility into and control over how companies spend money, as well as enables businesses to achieve savings that drive profitability. Its platform consists of procurement, invoicing, and expense management modules that form its transactional engine and capture a company's spend under management; and offers supporting modules, including sourcing, analytics, contract management, supplier management, inventory management, and storefront that help companies further manage their spend. The company markets its platform to a range of enterprises in various industries, such as healthcare and pharmaceuticals, retail, financial services, manufacturing, technology, and others primarily through a direct sales force worldwide. Coupa Software Incorporated has a strategic alliance with Aisino Corporation. The company was founded in 2006 and is headquartered in San Mateo, California.

#20 - Nektar Therapeutics (NASDAQ:NKTR)

Trailing Twelve Months EPS: ($0.55)
2018 EPS Estimate: ($1.43)
2019 EPS Estimate: ($1.75)

Current Price: $85.45
P/E Ratio: -155.4
Consensus Rating: Buy
Ratings Breakdown: 12 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $79.75 (-6.7% Upside)

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.

	10 Great Cheap Stocks to Buy Now for Under $10
	Top Ten Brokerages You Can Trust
	The Five Best Dow Jones Stocks to Buy Now
	Analysts Hate These 12 Stocks
	5 Best Cryptocurrency Stocks to Buy Now
	12 Stocks Corporate Insiders are Abandoning
	12 Marijuana Stocks to Buy Now